Fe(II), Ru(II) and Re(I) complexes of endotopic, sterically non-hindering, U-shaped 8,8'-disubstituted-3,3'-biisoquinoline ligands: syntheses and spectroscopic properties

[2]Catenanes built around octahedral transition-metal complexes that contain two intertwined endocyclic but non-sterically hindering tridentate ligands

Sterically hindering bidentate chelates, such as 2,9-diphenyl-1,10-phenanthroline, form entwined complexes with copper(I) and other tetrahedrally coordinated transition-metal centres. To prepare octahedral complexes containing two entwined tridentate ligands and thus apply a strategy similar to that used for making catenanes with tetrahedral metal centres, the use of the classical terpy ligand (terpy=2,2':6',2''-terpyridine) appears to be attractive. In fact, 6,6''-diphenyl-2,2':6',2''-terpyridine (dp-terpy) is not appropriate due to strong "pinching" of the organic backbone by coordination to the metal and thus stable entwined complexes with this ligand cannot be obtained. Herein, we report the synthesis and coordination properties of a new family of tridentate ligands, the main features of which are their endocyclic nature and non-sterically hindering character. The coordinating fragment consists of two 8'-phenylisoquinolin-3'-yl groups attached at the 2 and 6 positions of a pyridine nucleus. Octahedral complexes containing two such entangled ligands around an octahedral metal centre, such as Fe(II) , Ru(II) or Co(III) , are highly stable, with no steric congestion around the metal. By using functionalised ligands bearing terminal olefins, double ring-closing metathesis leads to [2]catenanes in good yield with Fe(II) or Co(III) as the templating metal centre. The X-ray crystallography structures of the Fe(II) precursor and the Fe(II) catenane are also reported. These show that although significant pinching of the ligand is observed in both Fe(II) complexes, the system is very open and no steric constraints can be detected.

Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing

Pyrazolopyridine inhibitors with low micromolar potency for CHK1 and good selectivity against CHK2 were previously identified by fragment-based screening. The optimization of the pyrazolopyridines to a series of potent and CHK1-selective isoquinolines demonstrates how fragment-growing and scaffold morphing strategies arising from a structure-based understanding of CHK1 inhibitor binding can be combined to successfully progress fragment-derived hit matter to compounds with activity in vivo. The challenges of improving CHK1 potency and selectivity, addressing synthetic tractability, and achieving novelty in the crowded kinase inhibitor chemical space were tackled by multiple scaffold morphing steps, which progressed through tricyclic pyrimido[2,3-b]azaindoles to N-(pyrazin-2-yl)pyrimidin-4-amines and ultimately to imidazo[4,5-c]pyridines and isoquinolines. A potent and highly selective isoquinoline CHK1 inhibitor (SAR-020106) was identified, which potentiated the efficacies of irinotecan and gemcitabine in SW620 human colon carcinoma xenografts in nude mice.